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Table 1 Regression Analysis of Survival
Variable
Relatie Risk of Mortality
(95% Confidence Interval)
P-
Value
DONOR TYPE
MSD* 1.0
MURD 1.5(0.6-3.9) .35
MMURD 4.7(1.9-11.7) <.01
UCB 1.8(0.8-4.0) .15
LENGTH OF FIRST
REMISSION
< 1 year* 1.0
> 1 year 0.5(0.3-1.0) .05
ALL T-CELL LINEAGE
No* 1.0
Yes 2.6(1.1-6.2) <.01
GRADE II-IV ACUTE GvHD
No* 1.0
Yes 0.5(0.2-1.1) .07
* Reference Category
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DIRECTED DONOR CORD BLOOD TRANSPLANTATION FOR HEMATO-
LOGICAL DISORDERS
Walters, M.C.1, Quirolo, L.1, Edwards, S.1, Lee, J.1, Robertson, S.1,
Falcon, K.2, Briddell, R.2, Lubin, B.1 1Children’s Hosp & Research
Center Oakland, Oakland, CA; 2Viacell, Inc., Boston, MA.
The Sibling Connection Program is a directed donor cord
blood program that accommodates sibling cord blood banking
from remote collection sites in the US. Between September
1997 and September 2006, 65 children were treated by sibling
donor cord blood transplantation (CBT) utilizing these cord
blood units (CBUs), 51 using cord blood as the sole source of
allogeneic hematopoietic cells. CBT recipients had acute leu-
kemia or myelodysplastic syndrome (N23), thalassemia major
(N21), sickle cell anemia (N12) or other non-malignant
disorders (N9), and all but 4 received HLA-identical sibling
allografts. The median total nucleated (TNC) cell dose was
4.9  107 TNC/kg recipient weight (range, 1.1 – 24.1) and the
median CD34 cell dose was 1.6  105/kg (range, 0.1 – 6.9).
The median time to absolute neutrophil count 500 and plate-
let 20,000/mm3 was 22 and 45 days, respectively. Of 60 pa-
tients who could be evaluated, 2 (3%) had graft rejection and
both had a non-malignant disorder treated by a non-myeloab-
lative regimen. Fourteen of 56 evaluable patients (25%) devel-
oped Grades I-III acute graft-versus-host disease (GVHD) and
none had Grade IV GVHD. Two of 48 evaluable patients had
chronic GVHD (4.2%) and both received HLA-mismatched
allografts. Overall, the Kaplan-Meier probabilities of survival
and event-free survival after sibling CBT are 80% and 76%,
respectively with a median follow-up of 16 months (range, 0.1 –
94 months). Patients died of relapse (N7), pulmonary toxicity
(N2), seizures (N1), or sepsis (N1) with an overall TRM of
6%. Outcome after CBT was best in patients with non-malig-
nant conditions, where 39 of 42 survive after CBT (93%) and 37
of 42 (88%) survive free of the underlying disorder. These
results conﬁrm the utility of remote site, directed donor cord
blood collection and subsequent transplantation for hematolog-
ical disorders. The ability to combine cord blood with a marrow
harvest from sibling donors generated a low risk of graft rejec-
tion and very low rates of severe GVHD. Transplantation of
sibling CBUs in lieu of bone marrow may be especially advan-
tageous when there is urgency for transplantation and in non-
malignant disorders where GVHD, in particular, has a negative
impact upon outcome.
SOLID TUMORS
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HIGH AVIDITY CYCLIN E-DERIVED PEPTIDE-SPECIFIC CTL CONTRIB-
UTE TO INDUCTION OF REMISSION AFTER STEM CELL TRANSPLANTA-
TION
Ishiyama, K.1, Kondo, Y.1,2, Wieder, E.1, Lu, S.1, Molldrem, J.1 1De-
partment of Stem Cell Transplantation and Cellular Therapy, The
University of Texas M.D. Anderson Cancer Center, Houston, TX;
2Cellular Transplantation Biology, Kanazawa University Graduate
School of Medical Sciences, Kanazawa, Ishikawa, Japan.
Cyclin E1 (CCNE1) and cyclin E2 (CCNE2) are cell cycle genes that
are overexpressed in AML, ALL, and CML, and in solid tumors such as
breast cancer (BrCA), lung cancer, and gastric cancer. We found that
cytotoxic T-lymphocytes (CTL) with speciﬁcity for two HLA-A2-re-
stricted CCNE1 (CCNE1144-152, ILLDWLMEV) and CCNE2
(CCNE2144-152, ILLDWLLEV) peptides killed tumors that overex-
pressed either protein, including ALL, CML, and non-Hodgkin’s lym-
phoma (NHL). Peptide/HLA-A2 tetramer binding assays and dissocia-
tion studies showed antigen cross-recognition, although CCNE1
appearedmore dominant. To determine the clinical signiﬁcance of CTL
immunity to these self-epitopes, we studied 18 leukemia patients (10
CML, 8 ALL) and 3 breast cancer patients before and after allogeneic
stem cell transplantation (SCT) using peptide/HLA-A2 tetramers. A
two-fold increase in CCNE1- or CCNE2-CTL after SCT was consid-
ered as evidence of an immune response (IR). Amongst 18 leukemia
patients, an IR to CCNE1 or to CCNE2 was found in 12 (67%) and 14
(78%) patients, respectively. All 12 patients with an IR to CCNE1 also
had an IR to CCNE2, reﬂecting possible cross-recognition of both
peptides by some CTL clones. IR to either CCNE1 or CCNE2 did not
correlate with diagnosis, source of the graft, or disease status prior to
SCT. Importantly, IR correlated with complete remission (CR) after
SCT (100% vs. 33%; p0.04), but IR occurred more frequently in
patients without graft-versus-host disease (GVHD) (92% vs. 50%,
p0.05). One BrCA patient had no clinical response and no IR after
SCT; however, two BrCA patients showed both clinical responses and
IRs to both cyclin peptides after SCT. One of these latter patients also
developed concomitant GVHD after tacrolimus withdrawal. In all 3
patients, CTL immunity to CMV did not change in proportion to
clinical response after SCT, suggesting that tumor-speciﬁc immunity
developed to cyclin E. These results provide clinical evidence that both
CCNE1 and CCNE2 peptides are novel tumor-associated antigens, and
they justify future studies to determine whether CTL immunity can be
enhanced against these antigens in cancer patients. Moreover, IR to
CCNE1 and CCNE2 correlates with SCT-induced remission in the
absence of acute GVHD, suggesting that the graft-versus-tumor effect
may be separable from GVHD.
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ENHANCING THE IN VIVO EXPANSION OF ADOPTIVELY TRANSFERRED
EBV-CTL WITH LYMPHODEPLETING CD45 MONOCLONAL ANTIBODIES
IN NPC PATIENTS
Louis, C.U.1, Straathof, K.1, Torrano, V.1, Huls, M.H.1,
Gresik, M.V.1, Weiss, H.1, Gee, A.1, Brenner, M.K.1, Rooney, C.M.1,
Heslop, H.E.1, Gottschalk, S.1 1Center for Cell and Gene Therapy:
Baylor College of Medicine, The Methodist Hospital and Texas Chil-
dren’s Hospital and Cancer Center, Houston, TX.
Background: Treatment of Epstein Barr virus (EBV)-positive naso-
pharyngeal carcinoma (NPC) with polyclonal EBV-speciﬁc cytotoxic T
cells (EBV-CTL) has been promising, producing disease stabilization and
complete remissions in patients with low disease burden. However, in-
fused EBV-CTL did not expand signiﬁcantly in vivo, limiting their anti-
tumor activity. One strategy to enhance the in vivo expansion of adop-
tively transferred CTL is to reduce the lymphocyte pool prior to T cell
infusion. This should result in homeostatic proliferation of the infused T
cells restoring the lymphoid compartment. A pair of monoclonal anti-
bodies, targeted to the CD45 antigen (CD45 MAbs), were used to
selectively lymphodeplete patients prior to stem cell transplantation.
These produced marked reduction in circulating lymphoid and myeloid
cells while largely sparing marrow progenitors. We therefore hypothe-
sized that administration of CD45 MAbs will lymphodeplete NPC pa-
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tients and allow for in vivo expansion of adoptively transferred EBV-
CTL.
Study design: The primary objective of this Phase I clinical trial is to
determine the safety of escalating doses of EBV-CTL after CD45MAbs
infusion in EBV-positive NPC patients. The secondary objective is to
determine the expansion, persistence and antitumor effects of infused
EBV-CTL.
Results: Eight patients with advanced stage, refractory/relapsed NPC
have been treated with autologous EBV-CTL (2107-1108 cells/m2
per infusion). Patients received between 1 - 5CTL infusions, which were
well tolerated, although one developed transient swelling at a pre-existing
metastatic disease site. Infusion of CD45 MAbs resulted in a transient
period of neutropenia (ANC 0.5109/L), which resolved within 48
hours. The absolute lymphocyte count decreased 4-fold and approached
baseline within 14 days post infusion. In 6 of 8 patients, we detected
increased IL-15 serum levels, a cytokine important for lymphocyte pro-
liferation. In 3 out of 8 patients EBV-CTL expanded 2.5 to 21-fold
within 8 weeks post infusion as determined by IFN- Elispot assays.
Clinically, 1 patient had a complete response (9 months), 3 had stable
disease for 2 - 16 months, and 4 had progressive disease.
Conclusion: Treatment of EBV-positive NPC with EBV-CTL ap-
pears to be safe and can be associated with signiﬁcant anti-tumor activity.
Administration of CD45 MAbs prior to EBV-CTL infusion resulted in
transient lymphodepletion and can aid in the expansion of adoptively
transferred CTL.
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REGULATION OF INITIAL SELF-RENEWING DIVISIONS OF HEMATOPOI-
ETIC STEM CELLS BY HUMAN MESENCHYMAL STROMAL CELLS
Wagner, W.1,2, Wuchter, P.1, Gottschling, S.1, Eckstein, V.1, Ho, A.D.1
1Department of Medicine V, Heidelberg, Germany; 2Department of
Physiology, Heidelberg, Germany.
To identify the signals controlling cell division symmetry and self-
renewal of hematopoietic stem cells (HSC) we have studied the cell-cell
contact between human HSC and human mesenchymal stem cells
(MSC) derived from themarrow, the latter serving as a surrogate “niche”
in vitro. By applying novel time lapsemicroscopy tomonitor cell divisions
ofHSCand correlating cell division symmetrywithLTC-ICormyeloid-
lymphoid initiating cell (ML-IC) assays at a single cell level, we have
previously demonstrated that only vital human MSC were able to drive
asymmetric divisions and maintain self-renewal. The roles of speciﬁc
homing and adhesion molecules, and of junctions between HSC and
MSCwere studied in the present report. In the ﬁrst 48 hours,  integrins
have been shown to be a major mediator of self-renewing divisions, as
well as CXCR4/SDF-1. However, ligands alone could not recapitulate
the effects of MSC. Subsequent to adhesion, junctions are formed be-
tween HSC and MSC. At the contact zone, N-cadherin, cadherin 11,
protein p120, - and -catenin are highly expressed, as demonstrated by
immunoﬂuorescence and Westernblot. Gene expression analyses have
also shown a signiﬁcant up-regulation of genes coding for adhesion
proteins and extracellular matrix in the adherent subsets of HSC (ﬁ-
bronectin 1, cadherin 11, connexin 43, N-cadherin, ITGBL1, VCAM1
and TGFB1). Upon incubation for further 72 hours, the genes that are
up-regulated in the HSC included the checkpoint (CHK1) homolog
(CHEK1), early growth response protein 1 (EGR-1) and a number of
genes coding for proteins that play a role in proliferation and DNA-
repair. Functionally LTC-IC were found almost exclusively among the
HSC adherent to MSC. Preliminary data from SCID mouse xenotrans-
plantation model indicated that the slow dividing fraction possessed sig-
niﬁcantly higher repopulating potential. Thus, albeit homing and adhe-
sion molecules such as -1- integrins, CXCR4/SDF-1 are essential for
mediating the initial cell-cell interactions leading to self-renewal divisions,
the formation of junctions and activation of the cadherin-catenin system
are essential steps for promotion of self-renewal of HSC by the cellular
niche.
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INCIDENCE AND MORTALITY OF INVASIVE FUNGAL INFECTIONS IN
HIGH-RISK PATIENTS RECEIVING POSACONAZOLE VERSUS FLUCON-
AZOLE OR ITRACONAZOLE PROPHYLAXIS
Langston, A.1, Lipton, J.H.2, Cornely, O.A.3, Ullmann, A.J.4, Patino, H.5,
Hardalo, C.5, Winston, D.J.6, Chandrasekar, P.7 1Emory University, At-
lanta, GA; 2Princess Margaret Hospital, Toronto, ON, Canada; 31st
Department of Internal Medicine, University of Cologne, Koln, Ger-
many; 4Johnannes Gutenberg University, Mainz, Germany; 5Schering-
Plough Research Institute, Kenilworth, NJ; 6University of California,
Los Angeles, Los Angeles, CA; 7Harper Hospital, Detroit, MI.
Background: In 2, multicenter, randomized trials (N1200), the
incidence of invasive fungal infection (IFI) and associated mortality
were investigated in patients receiving posaconazole (POS) vs ﬂu-
conazole (FLU) or itraconazole (ITZ).
Methods: In double-blind study, 1600 hematopoietic stem cell
transplant (HSCT) recipients with graft-vs-host disease (GVHD)
were randomized to receive POS oral suspension (200 mg t.i.d.) or
FLU tablets (400 mg q.d.). In study 2, 602 neutropenic patients
undergoing chemotherapy for acute myelogenous leukemia (AML)
or myelodysplastic syndrome (MDS) were randomized to receive
either 200 mg t.i.d. oral suspension POS or a standard azole (FLU
suspension 400 mg q.d. or ITZ solution 200 mg b.i.d.). The
incidence of proven/probable IFI was assessed by a blinded expert
panel for the on-treatment phase of study 1 (ﬁrst dose to last dose
plus 7 days) and study 2 (randomization to last dose plus 7 days).
Deaths from any cause during both studies were included in the
mortality analysis. Cause of death was investigator determined.
Results: In study 1, 600 patients were randomized to receive POS
(n301) or FLU (n299). In study 2, 602 patients were randomized to
receive POS (n304) or standard azole (FLU [n240] or ITZ [n58]).
During the on-treatment period, signiﬁcantly fewer IFIs developed in the
POS patient group in both study 1 (2% vs 8%, P0.004) and study 2
(2% vs 8%, P0.0009) compared to the FLUor standard azole (FLUor
ITZ) groups, respectively. In study 1, prophylaxis with POS resulted in
fewer IFIs than with FLU (5% vs 9%, P0.07) during the primary time
period (randomization to day 112). During the period from randomiza-
tion to day 100 in study 2, POS prophylaxis resulted in signiﬁcantly fewer
IFIs than prophylaxis with FLU or ITZ (5% vs 11%, P0.003). Fewer
cases of aspergillosis developed among patients receiving POS prophy-
laxis than among FLU or standard azole prophylaxis patients in both
study 1 (2% vs 7%, P0.006) and study 2 (1% vs 9%, P0.0001). A
signiﬁcant survival beneﬁt was demonstrated in AML/MDS patients
receiving POS prophylaxis (study 2) by Kaplan-Meier analysis of time to
death by any cause (P0.035).
Conclusion: In these 2 studies, prophylaxis with POS resulted in
fewer IFIs than prophylaxis with FLU or ITZ. Mortality rates in
both studies were higher in patients who developed an IFI than in
patients who did not, indicating that prophylaxis is a strategy that
prevents mortality in high-risk patients.
Overall Mortality During Study
Patients With IFI Patients Without IFI
Study 1 Study 2 Study 1 Study 2
n  62 n  32 n  538 n  570
Deaths, n (%) 40(65) 12(38) 120(22) 104(18)
Primary cause of death
IFIs 13(21) 8(25) 3(1)* 13(20)*
Underlying disease
(GVHD/malignancy) 10(16) 2(6) 54(10) 43(8)
Other complications 17(27) 2(6) 63(12) 48(8)
*Death attributed to IFI by investigator, but not considered due to
IFI by blinded expert panel
Oral Presentations 33
